How Much Does Prolia (Denosumab) Cost in Wisconsin in 2026?

Wisconsin Retail and Cash-Pay Pricing

The average cash-pay price for a single Prolia injection across Wisconsin retail pharmacies sits at approximately $1 to 500 in 2026, matching Amgen's wholesale acquisition cost. Prices can vary by $100 to $200 depending on the pharmacy and whether the injection is billed as a medical benefit (administered in-clinic under a provider's buy-and-bill model) or as a pharmacy benefit.

Hospital outpatient departments in Milwaukee, Madison, and Green Bay often add facility fees on top of the drug cost, pushing total charges to $1,800 or more per visit. Independent infusion centers and physician offices that buy the drug directly tend to bill closer to the wholesale price. Patients paying entirely out of pocket should request the drug's average sales price (ASP) reimbursement rate from their provider, since CMS publishes ASP data quarterly and Medicare Part B reimburses at ASP + 6%.

Because Prolia is dosed every six months, the annual drug cost alone is roughly $3,000 before any discounts or insurance. That figure does not include the office visit, which typically runs $50 to $150 for a nurse-administered subcutaneous injection. For context, the FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months compared to placebo, a degree of efficacy that informs payers' willingness to cover the drug.

Wisconsin Medicaid Coverage

Wisconsin Medicaid, administered through BadgerCare Plus and fee-for-service programs, covers Prolia with prior authorization. The PA process requires documentation that the patient has a confirmed diagnosis of osteoporosis (typically a DXA T-score of −2.5 or lower at the spine or hip), has tried or has a contraindication to at least one oral bisphosphonate such as alendronate, and is at high fracture risk.

Approval timelines vary. Standard PA decisions come back within 5 to 7 business days; urgent requests can be expedited to 24 hours. If a PA is denied, patients or their prescribers can file an appeal through the Wisconsin Department of Health Services (DHS). The Endocrine Society's 2020 clinical practice guideline supports denosumab as a first-line option for postmenopausal osteoporosis when oral bisphosphonates are inappropriate, a recommendation that strengthens PA appeals.

Managed care organizations (MCOs) that contract with Wisconsin Medicaid, including Quartz, Molina Healthcare, and Dean Health Plan, each maintain their own formulary criteria. Some MCOs require a step-through alendronate or risedronate before approving Prolia. Others accept a documented history of gastrointestinal intolerance or esophageal disorders as sufficient justification. Patients enrolled in Wisconsin SeniorCare, the state's pharmaceutical assistance program for residents age 65 and older, should verify whether Prolia falls under covered injectable medications, as SeniorCare primarily covers self-administered drugs.

Commercial Insurance in Wisconsin

Most commercial insurers operating in Wisconsin, including UnitedHealthcare, Anthem Blue Cross Blue Shield, Quartz, and Group Health Cooperative of South Central Wisconsin, cover Prolia on a specialty tier. Cost-sharing structures differ significantly between plans.

Under medical benefit coverage (J-code J0897 for denosumab), the patient typically owes a percentage coinsurance, often 20% after the deductible. On a $1,500 injection, that translates to $300 per dose before hitting the out-of-pocket maximum. Under pharmacy benefit coverage, the drug may be dispensed through a specialty pharmacy, and copays range from $50 to $500 depending on the plan's specialty tier structure.

The FDA-approved prescribing information for Prolia specifies that the drug must be administered by a healthcare professional, which means most plans classify it as a provider-administered injectable. Patients should call the number on the back of their insurance card and ask two specific questions: (1) Is denosumab covered under my medical benefit or pharmacy benefit? (2) What is my cost-sharing after the deductible?

High-deductible health plans (HDHPs) paired with health savings accounts (HSAs) are common among Wisconsin employers. For patients on these plans, the first injection of the calendar year often falls entirely within the deductible. The Amgen Savings Card (discussed below) can offset this cost for commercially insured patients.

The Amgen Savings Card and Other Discount Programs

Amgen's ENBREL/Prolia co-pay assistance program offers commercially insured patients up to $1,800 per calendar year toward their out-of-pocket Prolia costs. Patients with private insurance who meet income and coverage criteria can enroll at Amgen's patient assistance website or by calling the Amgen Safety Net Foundation.

Key details for Wisconsin patients:

The card applies only to out-of-pocket costs on commercial insurance. It does not apply to Medicare, Medicaid, TRICARE, or any other government-funded program. Patients must have commercial insurance that covers Prolia. The card reduces copays, coinsurance, or deductible obligations, but the maximum benefit is $1,800 per year (covering up to $900 per injection for the typical two-injection annual schedule).

For uninsured patients, Amgen's Safety Net Foundation provides Prolia at no cost to qualifying individuals. Eligibility is income-based, generally requiring household income below 300% of the federal poverty level (FPL). A family of four in Wisconsin earning under approximately $93 to 600 in 2026 would meet this threshold.

"For patients whose insurance does not cover denosumab or whose cost-sharing is prohibitive, manufacturer assistance programs remain the most impactful resource," notes the American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guideline.

Additional resources include GoodRx and RxAssist, which aggregate discount pricing but rarely reduce Prolia below $1,300 for cash-pay patients. Some Wisconsin hospital systems, including UW Health and Froedtert, have financial assistance programs that can cover specialty drug costs for patients who qualify based on income.

Compounded Denosumab in Wisconsin

Compounded denosumab is available in Wisconsin through licensed 503A compounding pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription.

A few points matter here. First, compounded denosumab is not FDA-approved. The FDA's guidance on compounding draws a clear distinction between commercially available biologics and compounded versions. Denosumab is a monoclonal antibody, and reproducing its exact structure through traditional compounding is not straightforward. What 503A pharmacies typically offer is a formulation that uses the same active ingredient but may differ in excipients, concentration, or stability profile.

Second, Wisconsin's Pharmacy Examining Board regulates 503A compounding pharmacies under state law. The pharmacy must hold a valid Wisconsin license and comply with USP 797 and USP 800 standards for sterile compounding. Patients should verify that the compounding pharmacy they use is licensed with the Wisconsin Department of Safety and Professional Services (DSPS).

Third, insurance coverage for compounded biologics is rare. Most commercial plans and Medicaid exclude compounded drugs from coverage, meaning patients pay the full cash price. Compounded denosumab pricing from 503A pharmacies varies widely but has been reported at significantly lower price points than the branded product.

The clinical evidence base for compounded denosumab is limited compared to branded Prolia, which was studied in trials enrolling over 11,000 patients. The FREEDOM extension study followed patients on branded denosumab for up to 10 years, demonstrating continued fracture risk reduction and progressive bone mineral density gains. No comparable long-term data exist for compounded formulations.

Medicare Part B and Part D Considerations

Wisconsin residents on Medicare represent a large share of Prolia users, since osteoporosis prevalence rises sharply after age 65. Prolia administered in a physician's office is covered under Medicare Part B as a provider-administered drug. The patient pays 20% coinsurance after the Part B deductible ($257 in 2025, adjusted annually). On a $1,500 injection, that comes to roughly $300 per dose, or $600 per year.

Medicare Supplement (Medigap) plans, popular in Wisconsin due to the state's guaranteed-issue protections, can cover some or all of the 20% coinsurance. Wisconsin uses a standardized Medigap system with a "basic plan" and optional riders, differing from the lettered plans (A through N) used in most other states. Patients should check whether their Medigap rider covers Part B coinsurance for specialty drugs.

"Denosumab is recommended for postmenopausal women at high risk of fracture, including those aged 65 and older with a T-score at or below −2.5," states the U.S. Preventive Services Task Force (USPSTF) screening recommendation. This recommendation supports Medicare coverage by establishing the clinical necessity of bone-density screening and subsequent treatment.

For the few situations where Prolia is dispensed through a specialty pharmacy rather than administered in-office, Medicare Part D may apply. Part D plans in Wisconsin, including those offered by Humana, SilverScript, and WellCare, place Prolia on specialty tiers with coinsurance ranging from 25% to 33%. The Part D catastrophic coverage threshold ($8 to 000 in true out-of-pocket costs in 2025, with the $2,000 cap under the Inflation Reduction Act now in effect) limits annual Prolia spending for Part D beneficiaries.

Telehealth Prescribing and Access

Wisconsin permits telehealth prescribing of Prolia. A provider licensed in Wisconsin can evaluate a patient via video or audio visit, review DXA results and lab work, and write or renew a Prolia prescription without an in-person visit. The Wisconsin Medical Examining Board upheld telehealth prescribing flexibilities that were expanded during the COVID-19 public health emergency, and state law (Wis. Stat. § 448.015) defines telehealth broadly enough to encompass specialty prescribing.

The injection itself still requires an in-person visit, since Prolia is administered subcutaneously by a healthcare professional. Patients in rural Wisconsin counties, where endocrinologists and rheumatologists are scarce, can use telehealth to obtain the prescription and then receive the injection at a local clinic or visiting nurse service.

Large Wisconsin health systems, including Marshfield Clinic Health System, Gundersen Health System, and Aspirus, offer telehealth endocrinology consultations that can initiate or manage Prolia therapy. Patients in the Fox Valley, Northwoods, and Western Wisconsin regions benefit most from this model, avoiding drives of 60 miles or more to see a specialist in person.

Reducing Your Out-of-Pocket Cost: A Step-by-Step Approach

Start by confirming how your plan covers Prolia. Call your insurer and ask whether it falls under medical or pharmacy benefit. Request the prior authorization form if one is required, and have your prescriber submit it with DXA results, fracture history, and documentation of any bisphosphonate trial or intolerance.

Next, apply for the Amgen Savings Card if you have commercial insurance. Enrollment takes under 10 minutes and can reduce each injection's cost by up to $900. If you are uninsured or underinsured, apply to the Amgen Safety Net Foundation.

If you are on Medicare, check whether your Medigap plan covers Part B coinsurance. Wisconsin's unique Medigap structure means not every plan includes this benefit. If your coinsurance burden is high, ask your provider about State Health Insurance Assistance Program (SHIP) counselors, who offer free help navigating Medicare drug costs.

For patients considering compounded denosumab, verify the pharmacy's Wisconsin DSPS license and ask for certificates of analysis documenting potency and sterility testing. Discuss the trade-offs with your prescriber, weighing lower cost against the absence of long-term clinical trial data for compounded formulations.

The 2024 Cochrane review on denosumab for postmenopausal osteoporosis confirmed that branded denosumab reduces vertebral fractures (RR 0.32 to 95% CI 0.26 to 0.41) and hip fractures (RR 0.60 to 95% CI 0.37 to 0.97) over 36 months, data that applies specifically to the FDA-approved formulation studied in the FREEDOM trial.

Prolia's labeled dose is 60 mg subcutaneously every 6 months, and missing or delaying doses can trigger rebound vertebral fractures within 7 to 12 months of discontinuation, per post-marketing analyses published in the Journal of Bone and Mineral Research. Wisconsin patients should set calendar reminders and confirm insurance re-authorization well before each scheduled injection.